IP Library Granted Patent US 8,703,429
Granted Patent B2
US 8,703,429 · App. 12/171,934 · Granted Apr 22, 2014

Composition exhibiting a von Willebrand Factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV

Inventors: Bernhard Laemmle (Bolligen, CH); Helena Elisabeth Schaller-Gerritsen (Muri, CH); Miha Furlan (Bern, CH); Peter Turecek (Klosterneuburg, AT); Hans-Peter Schwarz (Vienna, AT); Friedrich Scheiflinger (Vienna, AT); Gerhard Antoine (Gross-Enzersdorf, AT); Randolf Kerschbaumer (Klosterneuburg, AT); Luigina Tagliavacca (Milan, IT); Klaus Zimmermann (Pressbaum, AT)
Assignee: Baxler Innovations GmbH
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,703,429
App. No.
12/171,934
Granted
Apr 22, 2014
Kind
B2
Abstract

The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV, vWF cleaving complexes and methods for their production.

Claims (9)

1. A method for detection of vWF protease polypeptide in a sample comprising plasma, comprising the steps of:

(a) contacting the sample with a monoclonal antibody that binds to a polypeptide exhibiting vWF protease activity that comprises at least one single isolated peptide chain that is present in human plasma and has a molecular weight from about 180 kD to about 120 kD as determined by SDS-PAGE under reducing conditions and comprises the amino acid sequence AAGGILHLELLV (SEQ ID NO: 1); and

(b) detecting the complex, thereby detecting vWF protease polypeptide.

2. The method according to claim 1 , wherein the polypeptide to which the antibody binds comprises the amino acid sequence:

AAGGILHLELLVAVGPDVFQAHQEDTERYVLTNLNIGAELLRDPSLGAQFRVHLVKMVILTEPEG APNITANLTSSLLSVCGWSQTINPEDDTDPGHADLVLYITRFDLELPDGNRQVRGVTQLGGACS PTWSCLITEDTGFDLGVTI (SEQ ID NO:4).

3. The method according to claim 1 , wherein the antibody binds to the amino acid sequence AAGGILHLELLV.

4. The method according to claim 1 , wherein the polypeptide to which the antibody binds has a molecular weight of about 170 kD.

5. The method according to claim 1 , wherein the polypeptide to which the antibody binds has a molecular weight of about 160 kD.

6. The method according to claim 1 , wherein the polypeptide to which the antibody binds has a molecular weight of about 120 kD.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR NAME, EXECUTION DATE, AND ADDRESS OF ASSIGNEE BAXALTA GMBH PREVIOUSLY RECORDED ON REEL 036366 FRAME 0445. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Apr 4, 2016
From: BAXALTA INNOVATIONS GMBH
To: BAXALTA INCORPORATED; BAXALTA GMBH
Reel/Frame 038345/0889 →
CHANGE OF NAME Recorded Mar 29, 2016
From: BAXTER INNOVATIONS GMBH
To: BAXALTA INNOVATIONS GMBH
Reel/Frame 038292/0447 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER INNOVATIONS GMBH
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036366/0445 →
Continuity (4)
Continuation 11166288 · Jun 23, 2005
Division 09833328 · Apr 12, 2001
Continuation In Part 09721254 · Nov 22, 2000
Related Publication 20090017467A1 · Jan 15, 2009